INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 427m ago
HOUSE PTR27m ago
SEC 13F27m ago
ROBINHOOD CHAIN26m ago
Public company

First Tracks Biotherapeutics, Inc.

TRAXCIK 0002091349

EDGAR filingsOpen in network
Price$47.90
1 year+152.1%
Disclosed transactions60
Buys / sells0 / 1
Max Insider Score42
Connections with evidence8

TRAX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
SB
Stone BenjaminChief Business Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
42.5K sh
Nov 1, 2026Nov 3, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Stone BenjaminChief Business Officer · May 14, 2026
  • ← Insider ofevidence
    Tamboli AjimChief Financial Officer · Apr 23, 2026
  • ← Insider ofevidence
    Faga DanielDirector, President, CEO · Apr 22, 2026
  • ← Insider ofevidence
traded Nov 1, 2026
+2d
SEC FORM 4

Evidence

42
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Open-market sale
SELL$1.76M
39.3K sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

24
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Option exercise
M$225K
39.3K sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Option exercise
M—
28.6K sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Option exercise
M—
10.7K sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

21
SB
Stone BenjaminChief Business Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
60.5K sh
Aug 15, 2026Aug 18, 2026
traded Aug 15, 2026
+3dSEC FORM 4

Evidence

9
SB
Stone BenjaminChief Business Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
26.7K sh
May 12, 2026May 14, 2026
traded May 12, 2026
+2dSEC FORM 4

Evidence

9
SB
Stone BenjaminChief Business Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
72.3K sh
May 12, 2026May 14, 2026
traded May 12, 2026
+2dSEC FORM 4

Evidence

9
TA
Tamboli AjimChief Financial Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
5,000 sh
May 12, 2026May 14, 2026
traded May 12, 2026
+2dSEC FORM 4

Evidence

9
TA
Tamboli AjimChief Financial Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
13.6K sh
May 12, 2026May 14, 2026
traded May 12, 2026
+2dSEC FORM 4

Evidence

9
TA
Tamboli AjimChief Financial Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
41.2K sh
Apr 21, 2026Apr 23, 2026
traded Apr 21, 2026
+2dSEC FORM 4

Evidence

9
TA
Tamboli AjimChief Financial Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
41.2K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

9
TA
Tamboli AjimChief Financial Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
45.7K sh
Apr 21, 2026Apr 23, 2026
traded Apr 21, 2026
+2dSEC FORM 4

Evidence

9
TA
Tamboli AjimChief Financial Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
41.2K sh
Apr 22, 2026Apr 23, 2026
traded Apr 22, 2026
+1dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
70.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
67.1K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
115.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
97.2K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
29.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
6,145 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
21.1K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
25.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
21.4K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
JR
Jain RitaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
10.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
JR
Jain RitaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
8,015 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
JR
Jain RitaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
16.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
JR
Jain RitaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
16.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
JR
Jain RitaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
5,500 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
JR
Jain RitaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
1,300 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
11.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
2,321 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
9,200 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
194.9K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
379.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
305.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
133.4K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
17.9K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
69.4K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
80.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
98.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
784 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
11.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
9,200 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
10.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
16.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
16.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
5,500 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
6,030 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
MM
Marquet MagdaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
4,000 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
5,500 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
JR
Jain RitaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
6,030 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
6,000 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
6,030 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
JR
Jain RitaDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
4,000 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
28.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
10.7K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
6,000 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
11.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
11.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
TRAXFirst Tracks Biotherapeutics, Inc.
Grant or award
A—
9,200 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

Marquet Magda
Director · Apr 22, 2026
  • ← Insider ofevidence
    Ware J. AnthonyDirector · Apr 22, 2026
  • ← Insider ofevidence
    Lizzul Paul F.Chief Medical Officer · Apr 22, 2026
  • ← Insider ofevidence
    Jain RitaDirector · Apr 22, 2026